University of Cambridge, England.
Am J Clin Pathol. 2011 Jan;135(1):119-25. doi: 10.1309/AJCPOE11KEYZCJHT.
Current serum biomarkers for diagnosis and monitoring of malignant germ cell tumors (GCTs) show limited sensitivity and specificity. We previously observed that microRNAs of the miR-371∼373 and miR-302 clusters are overexpressed in all malignant GCTs, regardless of patient age, histologic subtype, or anatomic site, but are not reported to be coordinately up-regulated in other tumor types or disease states. Herein we show that levels of all 8 main members of the miR-371∼373 and miR-302 clusters were elevated in the serum of a 4-year-old boy at the time of diagnosis of yolk sac tumor. Levels returned to normal during an uneventful clinical follow-up, with kinetics similar to those of the conventional marker α-fetoprotein. We describe in detail the multiplex polymerase chain reaction protocol used to quantify serum microRNA levels, which is highly robust and reproducible. Our study indicates that miR-371∼373 and miR-302 cluster microRNAs are promising candidate biomarkers for improving disease monitoring (and potentially diagnosis) in malignant GCTs.
目前用于诊断和监测恶性生殖细胞肿瘤(GCT)的血清生物标志物的灵敏度和特异性均有限。我们之前观察到,miR-371∼373 和 miR-302 簇的 microRNAs 在所有恶性 GCT 中均过度表达,而与患者年龄、组织学亚型或解剖部位无关,但据报道在其他肿瘤类型或疾病状态中不会协调上调。在此,我们显示在卵黄囊瘤诊断时,一名 4 岁男孩的血清中 miR-371∼373 和 miR-302 簇的所有 8 个主要成员的水平均升高。在无并发症的临床随访期间,水平恢复正常,动力学与传统标志物甲胎蛋白相似。我们详细描述了用于定量血清 microRNA 水平的多重聚合酶链反应方案,该方案高度稳健且可重复。我们的研究表明,miR-371∼373 和 miR-302 簇 microRNAs 是改善恶性 GCT 疾病监测(和潜在诊断)的有前途的候选生物标志物。